encyclopedia jump navigation jump search multiple_sclerosis name multiple_sclerosis multiple_sclerosis multiple_sclerosis tissue macrophage area lesion multiple_sclerosis 
symptom vision blindness eye muscle weakness trouble sensation trouble coordination onset age duration term cause method symptom test treatment therapy year life expectancy frequency death 
multiple_sclerosis multiple_sclerosis disease cover nerve cell brain cord damage ability part system range sign symptom problem symptom vision blindness eye muscle weakness trouble sensation coordination multiple_sclerosis form symptom attack form time form attack symptom problem advancement disease 
cause mechanism destruction system failure cell cause genetics factor infection multiple_sclerosis present sign symptom result test 
cure multiple_sclerosis treatment function attack attack multiple_sclerosis side effect therapy people ability people treatment lack evidence benefit outcome outcome women disease life course attack life expectancy average year population 
multiple_sclerosis immune-mediate disorder system people rate region population year people multiple_sclerosis  disease age women men multiple_sclerosis name multiple_sclerosis scar plaque lesion matter brain cord number treatment method development multiple_sclerosis media video summary script content 
sign symptom cause geography genetics agent barrier diagnosis type management attack treatment symptom treatment epidemiology history discovery diagnosis case research disease insufficiency reference link 
sign symptom article multiple_sclerosis sign symptom symptom multiple_sclerosis 
person multiple_sclerosis symptom sign motor problem symptom location lesion system loss sensitivity change sensation pin needle numbness muscle weakness vision reflexe muscle spasm difficulty difficulty coordination balance problem speech problem optic vision feel pain bladder bowel difficulty difficulty think problem depression mood uhthoff phenomenon worsen symptom exposure temperature sign sensation back neck multiple_sclerosis measure disability severity disability status scale measure multiple_sclerosis research 
condition case syndrome cis number day motor problem optic symptom brainstem dysfunction difficulty course symptom pattern episode worsen day month relapse bout attack flare-up improvement case worsen time period recovery  case combination pattern people relapse course relapse warn year relapse trigger spring summer infection influenza gastroenteritis increase risk stress attack women multiple_sclerosis experience relapse month delivery risk pregnancy disability event relapse rate vaccination breast trauma phenomenon cause 
cause multiple_sclerosis result combination factor agent theory data explanation 
number risk factor research elimination multiple_sclerosis geography 
multiple_sclerosis people equator exception exception group risk equator samis canadian new zealand  
inuit group risk equator sicilian palestinian cause pattern north-south gradient incidence 
multiple_sclerosis region population variation distribution population sunlight exposure vitamin  production explanation relationship season birth multiple_sclerosis support idea people hemisphere november life factor role childhood study people region world age region risk multiple_sclerosis 
migration place age person risk home country evidence effect move people genetics hla region 
change area increase probability multiple_sclerosis 
multiple_sclerosis disease number variation risk gene level expression cell chance probability disease relative person risk twin time twin sible percentage half-sible parent risk children time population multiple_sclerosis group 
gene multiple_sclerosis difference leukocyte antigen hla systema group gene chromosome histocompatibility complex mhc difference hla region susceptibility region development autoimmune disease diabete type lupus find association multiple_sclerosis allele mhc dr15 locy effect hla difference account predisposition method association study gene hla locus probability multiple_sclerosis agent 
microbe trigger multiple_sclerosis age location world person risk multiple_sclerosis explanation kind infection microbe disease mechanism hygiene hypothesis prevalence hypothesis 
hygiene hypothesis exposure agent life disease response encounter agent prevalence hypothesis disease agent region multiple_sclerosis individual infection symptom 
case year hygiene hypothesis support prevalence hypothesis 
evidence virus cause presence band brain fluid people multiple_sclerosis association viruse demyelination occurrence demyelination animal infection herpe viruse candidate group viruse 
individual virus risk multiple_sclerosis adult risk age hygiene hypothesis upbring contradiction encounter virus life trigger disease disease measle mump rubella 
smoke risk factor multiple_sclerosis stress risk factor evidence association exposure toxinsmainly conclusion factor study association risk factor diet hormone intake evidence relation disease gout level acid people multiple_sclerosis 
theory acid importance article pathophysiology multiple_sclerosis multiple_sclerosis nerve axon myelin sheath 
characteristics multiple_sclerosis formation lesion system plaque inflammation destruction myelin sheath neuron 
feature complex manner breakdown nerve tissue turn sign symptom disease cholesterol crystal myelin repair inflammation multiple_sclerosis disorder interaction individual genetics cause damage part attack system person system demyelination multiple_sclerosis 
myelin stain area lesion 
name multiple_sclerosis scar plaque lesion form system 
lesion matter optic nerve brain stem ganglia cord matter tract ventricle function matter cell signal matter area process rest body 
multiple_sclerosis loss oligodendrocyte cell layerknown myelin sheathwhich neuron signal action potential result thine loss myelin disease breakdown axon neuron 
myelin neuron signal repair process place phase disease oligodendrocyte cell myelin sheath attack remyelination plaque axon scar origin symptom attack resonance image mry plaque number lesion brain consequence process creation lesion increase number due destruction neuron number lesion pattern 
sign disease inflammation 
explanation process  cell kind lymphocyte role body  cell gain entry brain disruption barrier 
 cell myelin attack cell lymphocyte 
attack myelin process cell release factor cytokine antibody 
breakdown barrier turn number effect activation macrophage activation cytokine protein transmission information neuron way factor neuron 
factor loss myelin axon barrier 
barrier bbb part system entry  cell system 
type cell infection virus bacteria 
infection  cell brain bbb mry breakdown diagnosis animation dissemination brain lesion time space study year multiple_sclerosis mri 
multiple_sclerosis present sign symptom combination image laboratory test sign symptom problem mcdonald criteria laboratory evidence lesion time area method diagnosis schumacher poser criteria significance 
data diagnosis multiple_sclerosis individual episode symptom characteristic disease attention attack test diagnosis 
tool analysis fluid potential 
resonance image brain spine area lesion plaque 
contrast agent plaque elimination existence lesion symptom moment evaluation test fluid lumbar puncture evidence inflammation system 
fluid band igg electrophoresis inflammation marker  people multiple_sclerosis system multiple_sclerosis stimulation optic nerve nerve demyelination pathway 
brain response potential 
criteria diagnosis state proof autopsy biopsy lesion multiple_sclerosis  test biopsy diagnosis disease type 
phenotype type pattern progression 
course disease attempt course 
prognosis treatment decision 
united states multiple_sclerosis society multiple_sclerosis federation type multiple_sclerosis 
syndrome cis multiple_sclerosis rr multiple_sclerosis multiple_sclerosis pp multiple_sclerosis multiple_sclerosis sp multiple_sclerosis 
multiple_sclerosis relapse period month year remission sign disease activity 
attack problem attack person disease course individual multiple_sclerosis deficit attack multiple_sclerosis people degree disability term hand term multiple_sclerosis people multiple_sclerosis level disability period subtype syndrome cis 
cis person attack demyelination criteria multiple_sclerosis person cis multiple_sclerosis 
multiple_sclerosis individual remission symptom progression disability onset remission improvement age onset subtype subtype 
age multiple_sclerosis year age 
multiple_sclerosis relapsing-remit multiple_sclerosis decline attack period remission relapse remission length time disease onset conversion relapsing-remit multiple_sclerosis year 
type multiple_sclerosis disease sclerosis sclerosis marburg multiple_sclerosis 
debate multiple_sclerosis variant disease multiple_sclerosis children time stage average age adult management article management multiple_sclerosis 
cure multiple_sclerosis therapy 
aim therapy function attack attack disability 
medication people attack lesion mri 
treatment medication management multiple_sclerosis effect 
treatment people shortage evidence 
attack administration dose corticosteroid therapy corticosteroid efficacy safety profile term symptom treatment impact recovery consequence attack corticosteroid treatment multiple_sclerosis 
medication agency relapsing-remitting multiple_sclerosis rr multiple_sclerosis 
interferon interferon acetate fingolimod dimethyl ocrelizumab 
cost effectiveness  march fda humanize antibody treatment rr multiple_sclerosis requirement phase trial 
rr multiple_sclerosis number attack interferon acetate treatment relapse early-initiate therapy outcome relapse rate agent issue effect agent treatment disease use effect option medication treatment syndrome cis interferon chance multiple_sclerosis efficacy interferon acetate children adult role agent teriflunomide dimethyl 
rituximab rr multiple_sclerosis multiple_sclerosis 
rituximab multiple_sclerosis march fda treatment multiple_sclerosis drug approval requirement phase trial 
medication mitoxantrone multiple_sclerosis population evidence support progression disease rate relapse year effect zone injection acetate 
treatment effect 
irritation injection site acetate interferon injection injection time dent injection site destruction tissue lipoatrophy symptom people experience reaction flush chest tightness heart palpitation anxiety minute liver damage dysfunction infertility myeloid multifocal natalizumab people 
rise hypertension heart rate liver enzyme reduction lymphocyte level evidence safety teriflunomide side effect headache fatigue nausea hair_loss limb pain report liver failure pml use development side effect dimethyl fumarate problem dimethyl fumarate reduction blood cell count case infection trial symptom 
medication neurorehabilitation symptom change course disease symptom response medication bladder spasticity problem approach quality life core team health service point time rehabilitation program increase activity participation people multiple_sclerosis impairment level evidence efficacy discipline evidence approache exercise therapy behavioral therapy multiple_sclerosis fatigue alternative treatment 
people multiple_sclerosis medicine percentage medicine evidence effectiveness treatment case treatment benefit people multiple_sclerosis supplementation regimen vitamin  relaxation technique yoga medicine cannabis oxygen therapy reflexology acupuncture mindfulness characteristics user women multiple_sclerosis time level satisfaction healthcare life year multiple_sclerosis inhabitant 32-68 77-88 119-119 470-910 
future course disease subtype disease individual sex age symptom degree disability person sex subtype optic symptom onset attack year age onset course 
life expectancy year start disease year people people multiple_sclerosis reach decade life death consequence disease suicide infection complication people ability death walk year onset update 
epidemiology death multiple_sclerosis person  
multiple_sclerosis autoimmune disorder system number people multiple_sclerosis rate region death year africa rate south east asia americas europe rate population descent number case year 
rate multiple_sclerosis diagnosis study populational pattern number theory cause 
multiple_sclerosis adult childhood year age subtype people autoimmune disorder disease women trend time women men children female male people male female history discovery detail draw multiple_sclerosis lesion brain stem cord 
robert carswell professor pathology jean cruveilhier professor anatomy disease detail disease carswell injury lesion cord atrophy microscope pathologist georg eduard  lesion blood vessel 
neurologist  person multiple_sclerosis disease report observation disease plaque 
attempt set criteria 
triad intention tremor speech scan speech cognition change patient enfeeblement memory conception 
diagnosis triad observation schumacher attempt criteria requirement dissemination lesion time space sign symptom disease process requirement criteria mcdonald criteria version use 
century theory cause pathogenesis treatment begine century refinement concept place 
revision mcdonald criteria diagnosis multiple_sclerosis lesion cis year revision phenotype disease course cis phenotype multiple_sclerosis expression conversion cis multiple_sclerosis case study locomotion female multiple_sclerosis walk difficulty 
account people multiple_sclerosis disease 
woman iceland vision mobility saint day 
saint lidwina schiedam nun people multiple_sclerosis 
age death pain weakness leg vision multiple_sclerosis case proposal vike gene hypothesis dissemination disease 
augustus frederick son prince augustus frederick duke sussex lady augusta murray grandson george united kingdom multiple_sclerosis 
diary year disease 
symptom age loss fugax funeral friend 
disease weakness leg clumsiness hand numbness dizziness bladder disturbance dysfunction 
illness view life account multiple_sclerosis diarist  
nom-de-plume bruce frederick cummings log diagnosis struggle diary journal man research article multiple_sclerosis research journal multiple_sclerosis multiple_sclerosis journal 
research treatment multiple_sclerosis creation therapy subtype strategy treatment 
  approval drug popularity frequency use drug investigation laquinimod estriol 
august phase trial result study efficacy ease use therapy 
use preparation version 
dose effect sex hormone concentration pregnancy candidate therapy women multiple_sclerosis phase trial request approval beta-1a 
antibody level interest 
alemtuzumab antibody ocrelizumab benefit study treatment fda relapse multiple_sclerosis march use appearance effect infection investigation development test jc virus antibody risk multifocal natalizumab antibody role treatment disease future risk 
research strategy effectiveness drug rationale number medication multiple_sclerosis treatment target mechanism use synergy drug effect drawback block action side-effect trial therapy result treatment multiple_sclerosis 
research neuroprotection treatment stem cell therapy importance stage treatment variant disease 
drug development therapy pp multiple_sclerosis sp multiple_sclerosis 
multiple_sclerosis entity presentation 
auto-antibody multiple_sclerosis case birth disease family concept multiple_sclerosis 
autoantibody optica multiple_sclerosis variant 
spectrum disease spectrum disease disease 
case multiple_sclerosis autoantibody variant 
autoantibody adem spectrum disease 
moment author disease 
kind auto-antibody 
anti-neurofascin damage node neurone 
antibody demyelination pp multiple_sclerosis demyelination multiple_sclerosis presentation 
autoantibody pattern demyelination multiple_sclerosis open door multiple_sclerosis disease disease brain scan phase sequence iron deposit matter lesion box middle image arrow corner 
criteria future work help diagnosis prediction disease progression method work antibody study serum fluid result 
time laboratory investigation prognosis 
approache oxide oxide synthase disease progression result degeneration neuron role protein loss nerve tissue tau investigation effect medication 
improvement technique positron emission tomography pet resonance image mry promise diagnosis prognosis prediction effect improvement practice decade mri technique usefulness research set practice recovery sequence transfer diffusion tensor resonance image technique disease standardization acquisition protocol creation value technique development contrast agent level macrophage inflammation dysfunction technique measure iron deposition role feature multiple_sclerosis perfusion pet marker process brain inflammation pathology apoptosis antibiody potassium channel multiple_sclerosis insufficiency article insufficiency 
surgeon paolo zamboni multiple_sclerosis narrow vein brain insufficiency 
patient multiple_sclerosis study procedure media liberation procedure participant theory attention media multiple_sclerosis canada concern research assumption cause disease data study relationship raise objection hypothesis liberation procedure complication death benefit  treatment multiple_sclerosis research hypothesis update 
list multiple_sclerosis organization list people multiple_sclerosis 
